Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.
Kathinka KrullMarina KunstreichAnnika BronsemaKirsten BleckmannCarl-Friedrich ClassenBernhard ErdlenbruchNorbert JorchReinhard KolbAlfred LeipoldOlga MoserAram ProkopWolfram ScheurlenDaniel SteinbachJanina Klasen-SansoneDirk KleeGabriele EscherichAnja MoerickeMartin SchrappeArndt BorkhardtMichaela KuhlenPublished in: Leukemia & lymphoma (2018)
Osteonecrosis (ON) is a common and debilitating side effect of anti-leukemic treatment in children with acute lymphoblastic leukemia (ALL). However, the impact of leukemia itself on ON development remains elusive. We analyzed 76 children enrolled in the ongoing OPAL trial, who had magnetic resonance imaging (MRI) studies at diagnosis. MRI screening revealed 14 osteonecrotic lesions (5 × hips, 9 × knees) of any grade (I-III) in 7 (9.2%) patients. Six months on, the number of ON per patient increased (1 patient), remained constant (2), and decreased (2). The severity increased from grade I to II in two patients, remained constant (1), completely resolved (2), and decreased from grade III to osteoedema (1). No differences between adolescents initially presenting with/without ON were observed concerning age, pubertal stage, body mass index, leukemia characteristics, and clinical presentation. In MRI screening, a remarkable number of adolescents with ALL present with ON at diagnosis. The course of these ON remains highly unpredictable.
Keyphrases
- magnetic resonance imaging
- acute lymphoblastic leukemia
- young adults
- end stage renal disease
- body mass index
- contrast enhanced
- ejection fraction
- acute myeloid leukemia
- chronic kidney disease
- newly diagnosed
- physical activity
- prognostic factors
- computed tomography
- case report
- squamous cell carcinoma
- clinical trial
- diffusion weighted imaging
- radiation therapy
- randomized controlled trial
- stress induced
- case control